Gene · 4103
Papers1,316
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,316
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Top advances of the year in autologous cellular therapy in melanoma and solid tumors. | Cancer | 2026 | 42734903 | PubTator, text mining | PubMed |
| MAGEA4 promotes gastric cancer progression by inducing chromosomal instability through the STAU1/c-Myc axis. | Cancer Genet | 2026 | 42673884 | PubTator, text mining | PubMed |
| Adult Undifferentiated Embryonal Sarcoma of the Liver with Spontaneous Tumor Rupture and Comprehensive Molecular Profiling: A Case Report. | Case Rep Oncol | 2026 | 42524507 | PubTator, text mining | PubMed |
| The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions. | Hum Vaccin Immunother | 2026 | 42517272 | PubTator, text mining | PubMed |
| Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies. | J Immunother Cancer | 2026 | 42476725 | PubTator, text mining | PubMed |
| Established and Emerging Less Invasive Biomarkers and Technologies for Lung Cancer Screening: Puerto Rican Context. | Onco (Basel) | 2026 | 42389670 | PubTator, text mining | PubMed |
| Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial. | Nat Med | 2026 | 42321382 | PubTator, text mining | PubMed |
| Screening of Demethylation-related Biomarkers and Exploration of Regulatory Mechanisms in Esophageal Cancer Patients Based on Machine Learning and Mendelian Randomization. | Curr Cancer Drug Targets | 2026 | 42261153 | PubTator, text mining | PubMed |
| MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial. | Nat Med | 2026 | 42219399 | PubTator, text mining | PubMed |
| The Landscape of Clinical Trials for TCR-T Cell Therapy. | Am J Clin Oncol | 2026 | 42184246 | PubTator, text mining | PubMed |
| Advances in cell therapy for solid tumours: European perspective and future directions. | Lancet Reg Health Eur | 2026 | 42099873 | PubTator, text mining | PubMed |
| Oncogenic MAGEA4 directs neuroendocrine differentiation and survival in prostate cancer cells through the SIRT1/Acetyl-p53/BCL-2 axis. | Mol Biol Rep | 2026 | 42084830 | PubTator, text mining | PubMed |
| Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with an in vitro-based safety approach. | Front Immunol | 2026 | 42079663 | PubTator, text mining | PubMed |
| UHRF1 drives subtype-independent aggressiveness and immune evasion in small cell lung cancer through PRC2 interactions. | iScience | 2026 | 42006373 | PubTator, text mining | PubMed |
| Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering. | Science | 2026 | 41855322 | PubTator, text mining | PubMed |
| Revisiting the Immune Frontier in Soft Tissue Sarcomas. | Curr Oncol Rep | 2026 | 41843220 | PubTator, text mining | PubMed |
| Neoadjuvant chemotherapy-induced immune remodeling in ovarian cancer: implications for TIL dynamics and combination immunotherapy. | Front Immunol | 2026 | 41798957 | PubTator, text mining | PubMed |
| Immunohistochemical Expression and Clinicopathological Assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 Expression in Desmoid Tumor. | Anticancer Res | 2026 | 41760259 | PubTator, text mining | PubMed |
| Ready or not, here they come: a practical guide to adoptive T-cell therapies for solid tumors for medical oncologists. | Oncologist | 2026 | 41739670 | PubTator, text mining | PubMed |
| Unveiling trends and clinical progress of immunotherapy for endometrial cancer: a scientometric and clinical trial landscape analysis. | Front Immunol | 2026 | 41737210 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4103/papers